The news Gilead Sciences dropped Monday was so disappointing it irked even the nicest guy in biotech.
Brad Loncar, an investor based in Kansas City whose cancer-focused exchange-traded fund holds Gilead shares, is a Ted Lasso-like font of cheeriness amid bio-Twitter’s angry froth. Yet even he was upset about the way Gilead and its CEO, Dan O’Day, released information about a key study of its breast cancer drug, Trodelvy — without any specific data. In 2020, Gilead had paid $21 billion for the drug and its maker, Immunomedics.